GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » EPS (Basic)

INNMF (Amplia Therapeutics) EPS (Basic) : $-0.02 (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics EPS (Basic)?

Amplia Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Sep. 2024 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.02.

Amplia Therapeutics's EPS (Diluted) for the six months ended in Sep. 2024 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.02.

Amplia Therapeutics's EPS without NRI for the six months ended in Sep. 2024 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Amplia Therapeutics EPS (Basic) Historical Data

The historical data trend for Amplia Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics EPS (Basic) Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.02 -0.01

Amplia Therapeutics Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - -0.01 -0.01

Amplia Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Amplia Therapeutics's Basic EPS for the fiscal year that ended in Mar. 2024 is calculated as

Basic EPS (A: Mar. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.953-0)/203.666
=-0.01

Amplia Therapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.905-0)/258.844
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (OTCPK:INNMF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Amplia Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.